Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.aurobindo.com | |
Market Cap | 30,653.38 Cr. | |
Enterprise Value(EV) | 30,554.65 Cr. | 2021-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 49.04 | Trailing Twelve Months Ending 2021-12 |
Price-Earning Ratio (PE) | 10.67 | Trailing Twelve Months Ending 2021-12 |
Industry PE | 28.07 | Trailing Twelve Months Ending 2021-12 |
Book Value / Share | 410.10 | Trailing Twelve Months Ending 2021-12 |
Price to Book Value | 1.28 | Calculated using Price: 523.30 |
Dividend Yield | 0.76 | Period Ending 2021-03 |
No. of Shares Subscribed | 58.59 Cr. | 585,938,609 Shares |
FaceValue | 1 | |
Company Profile | ||
Aurobindo Pharma commenced operations in 1988-89 with a single unit manufacturing Semi-Synthetic Penicillin (SSP) at Pondicherry. The company became a public company in 1992 and listed its shares on the Indian stock exchanges in 1995. In addition to being the market leader in Semi-Synthetic Penicillin’s, it has a presence in key therapeutic segments such as neurosciences (CNS), cardiovascular (CVS), anti-retroviral, anti-diabetics, gastroenterology and Anti-biotics. Through cost effective manufacturing capabilities and a few loyal customers, the company also entered the high margin specialty generic formulations segment. Today, it has evolved into a knowledge driven company manufacturing active pharmaceutical ingredients and formulation products. It is R&D focused and has a multi-product portfolio with manufacturing facilities in several countries. The formulation business is systematically organized with a divisional structure, and has a focused team for key international markets. The company’s units for APIs / intermediates and units for formulations are designed to meet the requirements of both advanced as well as emerging market opportunities. A well-integrated pharma company, the company features among the top 2 Pharmaceutical companies in India in terms of consolidated revenues. Aurobindo exports many countries across the globe with around 90% of revenues derived from international operations. Its customers include premium multi-national companies. With multiple facilities approved by leading regulatory agencies such as USFDA, EU GMP, UK MHRA, South Africa-MCC, Health Canada, WHO and Brazil ANVISA, Aurobindo makes use of in-house R&D for rapid filing of patents, Drug Master Files (DMFs), Abbreviated New Drug Applications (ANDAs) and formulation dossiers across the world. It is among the largest filers of DMFs and ANDAs in India. Business area of the company Aurobindo Pharma continues to be one of the world’s fastest growing Active Pharmaceutical Ingredients (API) manufacturing companies, driven by cost leadership, flexibility to produce multiple products in the same manufacturing facilities and capabilities in various therapeutic domains. Its API business has ensured the profitability and growth of its formulations business through seamless vertical integration. Its API business is supported by technologically advanced research and development infrastructure, which develops new products and plays a role in the delivery of products to the market. It has built a strong presence in key therapeutic segments such as Central nervous system (CNS), cardiovascular (CVS), anti-retroviral (ARV), anti-diabetics, gastroenterology and antibiotics. Also, it is building a diversified pipeline in high-margin specialty generic formulations segment. Awards & Accolades 2015-16:
2016-17:
2017-18:
2018-19:
2019-20:
Major Events and Milestones
|
1 Day |
|
-2.84% |
1 Week |
|
-6.46% |
1 Month |
|
-18.02% |
3 Month |
|
-16.29% |
6 Month |
|
-21.81% |
1 Year |
|
-48.82% |
2 Year |
|
-28.38% |
5 Year |
|
-0.48% |
10 Year |
|
+796.06% |
9 years | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
Return on Equity (%) | 11.78 | 36.79 | 35.29 | 32.51 | 27.57 | 22.99 | 18.47 | 18.62 | 27.81 | |
Return on Capital Employed (%) | 11.17 | 27.18 | 27.18 | 27.35 | 24.92 | 22.72 | 17.97 | 18.79 | 30.33 | |
Return on Assets (%) | 4.32 | 13.95 | 14.03 | 14.13 | 14.44 | 13.07 | 10.00 | 10.39 | 17.34 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2021-09* Rs. Cr. |
Shh. Funds | 2,606 | 3,750 | 5,156 | 7,287 | 9,372 | 11,680 | 13,891 | 16,825 | 21,930 | 23,418 | |
Non Curr. Liab. | 1,225 | 1,494 | 1,592 | 584 | 102 | 594 | 358 | 555 | 807 | 971 | |
Curr. Liab. | 3,431 | 4,220 | 6,136 | 7,840 | 6,606 | 8,666 | 12,021 | 11,385 | 10,665 | 9,206 | |
Minority Int. | 11 | 26 | 26 | 3 | 2 | 2 | 2 | 0 | -1 | -1 | |
Equity & Liab. | 7,273 | 9,490 | 12,910 | 15,714 | 16,082 | 20,942 | 26,271 | 28,765 | 33,401 | 33,594 | |
Non Curr. Assets | 3,136 | 3,859 | 4,611 | 5,420 | 6,875 | 8,764 | 10,939 | 12,352 | 13,578 | 14,937 | |
Curr. Assets | 4,137 | 5,631 | 8,299 | 10,294 | 9,206 | 12,178 | 15,332 | 16,413 | 19,824 | 18,657 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 7,273 | 9,490 | 12,910 | 15,714 | 16,082 | 20,942 | 26,271 | 28,765 | 33,401 | 33,594 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2021-12 Rs. Cr. TTM |
Net Sales | 5,855 | 8,100 | 12,121 | 13,795 | 14,910 | 16,463 | 19,564 | 23,099 | 24,775 | 23,648 | |
Other Income | 29 | 22 | 97 | 204 | 116 | 102 | 155 | 192 | 381 | 350 | |
Total Income | 5,884 | 8,121 | 12,217 | 13,998 | 15,025 | 16,565 | 19,719 | 23,290 | 25,155 | 23,997 | |
Total Expenditure | -4,994 | -5,966 | -9,557 | -10,607 | -11,475 | -12,691 | -15,612 | -18,234 | -19,441 | -18,961 | |
PBIDT | 889 | 2,155 | 2,660 | 3,392 | 3,550 | 3,874 | 4,107 | 5,056 | 5,714 | 5,037 | |
Interest | -267 | -310 | -160 | -257 | -67 | -78 | -263 | -305 | -74 | -58 | |
Depreciation | -249 | -313 | -333 | -392 | -428 | -558 | -668 | -967 | -1,055 | -1,139 | |
Taxation | -83 | -363 | -597 | -721 | -760 | -818 | -727 | -899 | -2,010 | -968 | |
Exceptional Items | -88 | -26 | 2,815 | 35 | |||||||
PAT | 291 | 1,169 | 1,571 | 2,022 | 2,296 | 2,420 | 2,362 | 2,859 | 5,389 | 2,908 | |
Minority Interest | 2 | 4 | 5 | 2 | 0 | 0 | 0 | 1 | 1 | 1 | |
Share Associate | 1 | 5 | 3 | 3 | -15 | -55 | -36 | ||||
Other Related Items | |||||||||||
Consolidated Net Profit | 294 | 1,173 | 1,576 | 2,025 | 2,302 | 2,423 | 2,365 | 2,845 | 5,335 | 2,873 | |
Adjusted EPS | 5 | 20 | 27 | 35 | 39 | 41 | 40 | 49 | 91 | 49 |
Particulars | 10 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
Cash Fr. Operatn. | 326 | 275 | 646 | 1,237 | 1,420 | 3,279 | 1,955 | 1,651 | 4,381 | 3,329 | |
Cash Fr. Inv. | -563 | -246 | -819 | -1,398 | -1,445 | -1,787 | -1,927 | -2,903 | -1,568 | 599 | |
Cash Fr. Finan. | 119 | 108 | 118 | 93 | 365 | -1,915 | 864 | 1,919 | -1,947 | -1,365 | |
Net Change | -118 | 137 | -55 | -68 | 340 | -424 | 892 | 667 | 866 | 2,563 | |
Cash & Cash Eqvt | 66 | 203 | 148 | 461 | 744 | 320 | 1,210 | 1,876 | 2,747 | 5,330 |
Mon, 23 May 2022
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011 The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on May 23 2022 for K Nityananda Reddy |
Fri, 20 May 2022
Board Meeting Intimation for Intimation Of Board Meeting. AUROBINDO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2022 inter alia to consider and approve We hereby inform pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 that a Meeting of the Board of Directors of the Company will be held on Monday May 30 2022 to consider and approve inter alia the following:1. Standalone & Consolidated Audited Financial Results of the Company for the fourth quarter and year ended March 31 2022 and 2. Payment of Fourth Interim Dividend if any for the financial year 2021-22. Please note that the record date for the purpose of determining the entitlement of the equity shareholders for the aforesaid interim dividend if declared is fixed as Friday June 3 2022. |
Fri, 20 May 2022
Record Date For Interim Dividend We hereby inform pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 that a Meeting of the Board of Directors of the Company will be held on Monday May 30 2022 to consider and approve inter alia the following:1. Standalone & Consolidated Audited Financial Results of the Company for the fourth quarter and year ended March 31 2022 and2. Payment of Fourth Interim Dividend if any for the financial year 2021-22. Please note that the record date for the purpose of determining the entitlement of the equity shareholders for the aforesaid interim dividend if declared is fixed as Friday June 3 2022. |
Wed, 25 May 2022 |
|
|
|
|
|